TR200000291T2 - Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler. - Google Patents

Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.

Info

Publication number
TR200000291T2
TR200000291T2 TR2000/00291T TR200000291T TR200000291T2 TR 200000291 T2 TR200000291 T2 TR 200000291T2 TR 2000/00291 T TR2000/00291 T TR 2000/00291T TR 200000291 T TR200000291 T TR 200000291T TR 200000291 T2 TR200000291 T2 TR 200000291T2
Authority
TR
Turkey
Prior art keywords
receptor antagonists
acylaminopropanamines
tachykinin receptor
tachykinin
disease
Prior art date
Application number
TR2000/00291T
Other languages
English (en)
Inventor
Erwin Fritz James
Arthur Hipskind Philip
Warren Kaldor Stephen
Lynn Lobb Karen
Arthur Nixon James
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200000291T2 publication Critical patent/TR200000291T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Alzheimer hastaligi dahil çesitli sartlarin tedavisinde kullanisli peptidil olmayan tasikinin reseptör antagonistleri ve bu terkipleri ihtiva eden farmasötik formülasyonlar ifsa edilmistir.
TR2000/00291T 1997-08-06 1998-08-06 Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler. TR200000291T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5499797P 1997-08-06 1997-08-06

Publications (1)

Publication Number Publication Date
TR200000291T2 true TR200000291T2 (tr) 2000-07-21

Family

ID=21994906

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00291T TR200000291T2 (tr) 1997-08-06 1998-08-06 Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.

Country Status (17)

Country Link
US (1) US6358994B1 (tr)
EP (1) EP1005454A4 (tr)
JP (1) JP2001512715A (tr)
KR (1) KR20010022581A (tr)
CN (1) CN1272842A (tr)
AU (1) AU8693398A (tr)
BR (1) BR9811821A (tr)
CA (1) CA2298701A1 (tr)
EA (1) EA200000198A1 (tr)
HR (1) HRP20000065A2 (tr)
HU (1) HUP0002929A3 (tr)
ID (1) ID24468A (tr)
IL (1) IL134301A0 (tr)
NO (1) NO20000519L (tr)
PL (1) PL338453A1 (tr)
TR (1) TR200000291T2 (tr)
WO (1) WO1999007677A1 (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2298702A1 (en) * 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
EP1385577B1 (en) * 2001-04-23 2006-04-19 F. Hoffman-la Roche AG Use of nk-1 receptor antagonists against benign prostatic hyperplasia
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
SI1501808T1 (sl) * 2002-04-26 2008-10-31 Lilly Co Eli Antagonisti tahikininskega receptorja
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ563687A (en) * 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2011104307A2 (en) * 2010-02-25 2011-09-01 Graffinity Pharmaceuticals Gmbh Ligands for antibody purification by affinity chromatography
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340588C (en) 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5278316A (en) * 1989-06-29 1994-01-11 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
AU4713293A (en) * 1992-07-13 1994-01-31 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
CA2140640A1 (en) 1992-08-13 1994-03-03 David C. Horwell Tachykinin antagonists
AU5342894A (en) 1992-10-30 1994-05-24 Merck Sharp & Dohme Limited Tachykinin antagonists
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5491140A (en) 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
AU688072B2 (en) * 1994-07-12 1998-03-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists

Also Published As

Publication number Publication date
PL338453A1 (en) 2000-11-06
CA2298701A1 (en) 1999-02-18
HRP20000065A2 (en) 2001-04-30
WO1999007677A1 (en) 1999-02-18
HUP0002929A3 (en) 2002-01-28
EP1005454A1 (en) 2000-06-07
HUP0002929A2 (hu) 2001-10-28
EP1005454A4 (en) 2003-01-15
EA200000198A1 (ru) 2000-10-30
CN1272842A (zh) 2000-11-08
US6358994B1 (en) 2002-03-19
NO20000519L (no) 2000-03-31
BR9811821A (pt) 2000-08-15
IL134301A0 (en) 2001-04-30
AU8693398A (en) 1999-03-01
KR20010022581A (ko) 2001-03-26
NO20000519D0 (no) 2000-02-01
ID24468A (id) 2000-07-20
JP2001512715A (ja) 2001-08-28

Similar Documents

Publication Publication Date Title
ID28003A (id) Turunan-turunan adamantana
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
FR2696094B1 (fr) Nouvelles compositions pharmaceutiques contenant des cyclosporines.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
ATE2667T1 (de) Antidepressiv wirkende derivate des trans-4phenyl-1,2,3,4-tetrahydro-1-naphthalin-amins und pharmazeutische zusammensetzungen daraus.
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
EP1409544A4 (en) HUMAN DR4 ANTIBODIES AND ITS APPLICATIONS
DE69842237D1 (de) Azeotropische Zusammensetzungen enthaltend 1,1,1,2,3,3,3-Heptafluorpropan und Verfahren, die diese Zusammensetzungen verwenden
ATE231872T1 (de) Thiazolopyrimidinderivate
ATE355269T1 (de) Phenylalaninderivate
SE9201628D0 (sv) Pharmaceutical composition
BG105256A (en) Muscarinic agonists and antagonists
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
TR199901385T2 (tr) Piperidin türevleri.
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
DE69831737D1 (de) Neurotrypsin
SE0001916D0 (sv) Novel formulation
ATE198481T1 (de) Bizyclische tachykinin-antagonisten, deren herstellung und deren verwendung in pharmazeutischen zusammmensetzungen